Cancer of the Tongue Clinical Trial
— FAITHOfficial title:
Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen
In head and neck cancer, areas of tumours with low oxygen supply (called tumour hypoxia) harbour cells that are resistant to radiation and are prone to metastasize. Modern radiotherapy techniques are precise enough to deliver radiation to these small areas and could be used to target these areas to receive higher doses of radiation than the rest of the tumour to overcome resistance. Hypoxia can be "seen" in the body using special imaging such as [F-18]-FAZA-PET ([F-18]-Fluoroazomycin arabinoside positron emission tomography) but it has not been tested as a method for creating radiation treatment targets. As part of regular pathology tumour tissue is sliced extremely thinly (<1/100th of a millimeter) and stained so that individual cells can be seen under a microscope. Immunohistochemistry (IHC) is a special type of "stain" that can specifically highlight hypoxic areas. This method is considered the most accurate way to inspect for the presence of hypoxia. There is not a specific staining target for hypoxia ordinarily, but when patients ingest a substance called pimonidazole-HCl it builds up specifically in hypoxic areas and can be targeted for IHC staining. In this study participants with oral tongue cancer will have a [F-18]-FAZA-PET scan and take a single dose of oral pimonidazole-HCl before having surgery to remove their cancer. The whole tumour will be used to create microscope slides using very thin slices of the tumour. The slices will be stained using IHC to show where the pimonidazole has built up. Digital scans of the slides will be made using a laser scanner. The hypoxia seen on their FAZA-PET scan will be "matched" with hypoxia on the electronic slides to see if the FAZA truly shows where hypoxia is in tumours and if it could be used as a way to plan radiation treatments to deliver more radiation to just those areas.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female patients = 18 years old - Biopsy proven Stage II-III oral tongue squamous cell carcinoma - Patients must be naïve to treatment for resectable disease - Surgical resection as definitive treatment modality - Ability to participate and willingness to give written informed consent prior to performance of any study-related procedures and to comply with the study protocol - Adequate hematologic, renal and liver function as defined by the following laboratory values (upper limit of normal, ULN, as per Sunnybrook Reference Test Manual) performed prior to admission to the Odette Cancer Centre: - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelet count = 50 ×109/L - Hemoglobin = 9 g/dL - Bilirubin = 1.5 × the upper limit of normal ULN (20.0 µmol) - AST, ALT, and alkaline phosphatase = 2.5 × the ULN (37 U/L, 40 U/L, 120 U/L) - Serum creatinine = 1.5 × the ULN (106 µmol/L) or creatinine clearance = 50 mL/min on the basis of the Cockroft-Gault glomerular filtration rate estimation: [(140-age) × (weight in kg × (0.85 if female)]/[72 × (serum creatinine in mg/dL)] - Prothrombin time (PT), international normalized ratio (INR), partial thromboblastin time (PTT) = 1.5 × the ULN (respectively 1.1, 14 sec, 35 sec) - Negative serum pregnancy test within 14 days prior to commencement of dosing in women of childbearing potential. Women of non-childbearing potential need not undergo pregnancy testing. Exclusion Criteria: - Patients who have received prior chemotherapy or radiation therapy for their oral tongue carcinoma - Stage I, Stage III T1/N1/M0, and Stage IV disease - Pregnancy or breastfeeding at the time of consent |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sunnybrook Health Sciences Centre | Cancer Care Ontario, Princess Margaret Hospital, Canada, Sunnybrook Research Institute, University of Toronto, University of Western Ontario, Canada |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Defining an hypoxic radiation target | To define a reference standard hypoxic radiation target through the correlation of functional F18-FAZA PET imaging to a pimonidazole-stained 3D whole mounted histological specimen. | 2-3 years from study initiation | No |
Primary | Correlation of FAZA-PET hypoxia to pimonidazole stained histology | To determine the degree to which hypoxic signal measured by FAZA-PET imaging is correlated with true cellular hypoxia confirmed by immunohistochemical staining of pimonidazole using a 3D whole-mount approach. | 2-3 years from study initiation | No |
Secondary | Quality of co-registration techniques | To assess quality of registration through measuring registration error of various automatic and semi-automatic co-registration techniques. | 1-3 years from study initiation | No |
Secondary | Correlation of textural features | To evaluate potential relationships between textural features of MRI, PET-CT, and immunohistochemistry. | 2-3 years from study initiation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03305302 -
Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL
|
||
Active, not recruiting |
NCT03853655 -
Adjuvant Radiotherapy in Early Stage Oral Cancers
|
N/A |